Jenny Jia Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jenny Jia Yu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Leonid Churilov
Melbourne Brain Centre at the Royal Melbourne Hospital
2 shared publications- Leonid Churilov
Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia
2 shared publications Nawaf Yassi
Melbourne Brain Centre at the Royal Melbourne Hospital
2 shared publications- Nawaf Yassi
Department of Medicine, Royal Melbourne Hospital, Parkville, Australia
2 shared publications - Paula Loveland
Departments of Medicine and Neurology Melbourne Brain Centre at The Royal Melbourne Hospital Department of Medicine University of Melbourne Parkville Victoria Australia
2 shared publications Rosie Watson
Melbourne Brain Centre at the Royal Melbourne Hospital
2 shared publications
Latest Publications
- Open Access
Plasma Neurofilament Light Chain is Markedly Elevated in General Hospital Inpatients with Delirium
Objective: To determine whether plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are elevated in hospitalised patients with delirium relative to patients with dementia and primary psychiatric disorders (PPD). Methods and analysis: This was a cross-sectional observational study conducted at the Royal Melbourne Hospital, Melbourne, Australia, between April and October 2024, with comparator samples from a research biobank. In Phase 1 (Delirium Discovery Cohort), we measured plasma NfL and GFAP using the Single molecule array (Simoa) platform in hospitalised patients with delirium and compared them with dementia and PPD groups. Biomarker concentrations were the primary outcome and were compared using general linear models adjusted for age, sex, and estimated glomerular filtration rate, with bootstrapped confidence intervals. Discriminative performance was assessed as a secondary outcome using receiver operating characteristic (ROC) curve analysis,. In Phase 2, we applied this threshold to independent dementia and PPD groups. Results: In Phase 1 (n =176), inpatients with delirium showed higher concentrations of both NfL and GFAP than patients with dementia (β = 0.78; 95% CI [0.37, 1.20] and β = 0.39 [0.07, 0.73] respectively) or PPD groups (β = 1.17; [0.69, 1.66] and β = 0.83 [0.51, 1.24] respectively). ROC curve analysis for differentiating delirium from dementia and PPD groups yielded an optimal NfL threshold of 24.1 pg/mL (AUC = 0.89, 96% sensitivity, 70% specificity). In comparison, GFAP showed lower accuracy (AUC = 0.85), and combining NfL with GFAP (AUC = 0.90) did not significantly improve performance. In Phase 2 (n = 154), the NfL threshold of > 24 pg/ml maintained strong performance (AUC = 0.95, 96% sensitivity, and 77% specificity). Conclusions: Plasma NfL shows promise as a biomarker for delirium in hospitalised patients, distinguishing it with high sensitivity from patients with dementia and PPD. Larger multicentre studies are needed to refine cut-offs, evaluate temporal dynamics, and determine integration into acute hospital delirium pathways. What is already known on this topic: Delirium is highly prevalent in general hospitals but remains frequently underdiagnosed. Currently, no validated blood-based biomarker exists to reliably assist in clinical identification. What this study adds: Plasma neurofilament light chain (NfL) is substantially elevated in general hospital inpatients with delirium compared to those with dementia or primary psychiatric disorders. This includes patients with delirium superimposed on dementia, yielding a discriminative profile well-suited for ruling out the diagnosis. How this study might affect research, practice or policy: These findings support the prospective evaluation of plasma NfL as an objective adjunct to clinical bedside assessments. This biomarker could significantly aid in evaluating patients with acute confusion, particularly when hypoactive presentations make clinical diagnosis challenging.
Open AccessPlasma Neurofilament Light Chain is Markedly Elevated in General Hospital Inpatients with Delirium
Objective: To determine whether plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are elevated in hospitalised patients with delirium relative to patients with dementia and primary psychiatric disorders (PPD). Methods and analysis: This was a cross-sectional observational study conducted at the Royal Melbourne Hospital, Melbourne, Australia, between April and October 2024, with comparator samples from a research biobank. In Phase 1 (Delirium Discovery Cohort), we measured plasma NfL and GFAP using the Single molecule array (Simoa) platform in hospitalised patients with delirium and compared them with dementia and PPD groups. Biomarker concentrations were the primary outcome and were compared using general linear models adjusted for age, sex, and estimated glomerular filtration rate, with bootstrapped confidence intervals. Discriminative performance was assessed as a secondary outcome using receiver operating characteristic (ROC) curve analysis,. In Phase 2, we applied this threshold to independent dementia and PPD groups. Results: In Phase 1 (n =176), inpatients with delirium showed higher concentrations of both NfL and GFAP than patients with dementia (β = 0.78; 95% CI [0.37, 1.20] and β = 0.39 [0.07, 0.73] respectively) or PPD groups (β = 1.17; [0.69, 1.66] and β = 0.83 [0.51, 1.24] respectively). ROC curve analysis for differentiating delirium from dementia and PPD groups yielded an optimal NfL threshold of 24.1 pg/mL (AUC = 0.89, 96% sensitivity, 70% specificity). In comparison, GFAP showed lower accuracy (AUC = 0.85), and combining NfL with GFAP (AUC = 0.90) did not significantly improve performance. In Phase 2 (n = 154), the NfL threshold of > 24 pg/ml maintained strong performance (AUC = 0.95, 96% sensitivity, and 77% specificity). Conclusions: Plasma NfL shows promise as a biomarker for delirium in hospitalised patients, distinguishing it with high sensitivity from patients with dementia and PPD. Larger multicentre studies are needed to refine cut-offs, evaluate temporal dynamics, and determine integration into acute hospital delirium pathways. What is already known on this topic: Delirium is highly prevalent in general hospitals but remains frequently underdiagnosed. Currently, no validated blood-based biomarker exists to reliably assist in clinical identification. What this study adds: Plasma neurofilament light chain (NfL) is substantially elevated in general hospital inpatients with delirium compared to those with dementia or primary psychiatric disorders. This includes patients with delirium superimposed on dementia, yielding a discriminative profile well-suited for ruling out the diagnosis. How this study might affect research, practice or policy: These findings support the prospective evaluation of plasma NfL as an objective adjunct to clinical bedside assessments. This biomarker could significantly aid in evaluating patients with acute confusion, particularly when hypoactive presentations make clinical diagnosis challenging.
- 23 March 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
The Neuropsychiatric Symptom Profile of Mild Dementia With Lewy Bodies
Introduction: Neuropsychiatric symptoms are often considered late manifestations of dementia and can be neglected during early clinical assessments. Besides visual hallucinations, less is known about other neuropsychiatric symptoms in mild dementia with Lewy bodies (DLB). We aimed to 1) describe neuropsychiatric symptoms and associated caregiver distress in mild DLB; 2) describe neuropsychiatric symptoms stratified by dementia stage within the included participants. Methods: Individuals with probable DLB and their caregivers underwent clinical and neuropsychiatric assessments. Clinical Dementia Rating Global Score (CDR-G) of 0.5 (denoting “very mild dementia”) was used to stratify the participants into earlier and later stage subgroups. The Neuropsychiatric Inventory (NPI) was used to assess neuropsychiatric symptoms. Median regression was used to estimate the difference in symptom severity and caregiver distress between the subgroups. Results: Fifty participants (age 73.5 ± 5.7 years, 43 males, median mini mental state exam (MMSE) 26 [IQR 23 - 27], median CDR 0.5 [IQR 0.5 - 1]) were enrolled. Twenty-six had earlier and 24, later stage dementia. Neuropsychiatric symptoms were common across both subgroups (96.2% and 95.8% prevalence respectively), with apathy, anxiety and depression being most prevalent (≥50% prevalence). Overall symptom severity was similar between the subgroups, although caregivers of the later stage subgroup reported more distress. Conclusion: Neuropsychiatric symptom, especially apathy, anxiety and depression, are extremely common in mild DLB. Assessment of neuropsychiatric symptoms is therefore an essential part of clinical care in DLB, starting from initial presentation. Future studies should consider factors other than symptom severity that contribute to caregiver distress.
- 23 March 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
The Neuropsychiatric Symptom Profile of Mild Dementia With Lewy Bodies
Introduction: Neuropsychiatric symptoms are often considered late manifestations of dementia and can be neglected during early clinical assessments. Besides visual hallucinations, less is known about other neuropsychiatric symptoms in mild dementia with Lewy bodies (DLB). We aimed to 1) describe neuropsychiatric symptoms and associated caregiver distress in mild DLB; 2) describe neuropsychiatric symptoms stratified by dementia stage within the included participants. Methods: Individuals with probable DLB and their caregivers underwent clinical and neuropsychiatric assessments. Clinical Dementia Rating Global Score (CDR-G) of 0.5 (denoting “very mild dementia”) was used to stratify the participants into earlier and later stage subgroups. The Neuropsychiatric Inventory (NPI) was used to assess neuropsychiatric symptoms. Median regression was used to estimate the difference in symptom severity and caregiver distress between the subgroups. Results: Fifty participants (age 73.5 ± 5.7 years, 43 males, median mini mental state exam (MMSE) 26 [IQR 23 - 27], median CDR 0.5 [IQR 0.5 - 1]) were enrolled. Twenty-six had earlier and 24, later stage dementia. Neuropsychiatric symptoms were common across both subgroups (96.2% and 95.8% prevalence respectively), with apathy, anxiety and depression being most prevalent (≥50% prevalence). Overall symptom severity was similar between the subgroups, although caregivers of the later stage subgroup reported more distress. Conclusion: Neuropsychiatric symptom, especially apathy, anxiety and depression, are extremely common in mild DLB. Assessment of neuropsychiatric symptoms is therefore an essential part of clinical care in DLB, starting from initial presentation. Future studies should consider factors other than symptom severity that contribute to caregiver distress.
- Open Access
- 3 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70425
The prevalence of apathy in Lewy body dementia: A systematic review and meta‐analysis
INTRODUCTION: Apathy is an important syndrome in Lewy body dementia (LBD), although reported prevalences vary. We aimed to estimate the prevalence of apathy in LBD through systematic review and meta‐analysis. METHODS: Five databases were searched for articles reporting the prevalence of apathy in LBD (dementia with Lewy bodies [DLB] and Parkinson's disease dementia [PDD]) and prodromal/mild cognitive impairment (MCI) LBD. Linear mixed model random effect meta‐analysis was performed to determine the prevalence of apathy. RESULTS: Of 7846 articles identified, 49 met inclusion criteria. The average pooled prevalence of apathy was 57% (95% confidence interval [CI] 52%–63%, I 2 = 85.6%) in DLB, 56% (95% CI 43%–70%, I 2 = 97.6%) in PDD, 46% (95% CI 32%–61%, I 2 = 90.6%) in Lewy body‐MCI, and 38% (95% CI 25%–50%, I 2 = 88.1%) in Parkinson's disease‐MCI. DISCUSSION: Apathy affects more than half of individuals with LBD. The high prevalence in prodromal DLB supports the notion that apathy may assist in more timely and accurate diagnosis of DLB. Highlights: Reported apathy prevalence in Lewy body dementia (LBD) varies widely in the existing literature. The pooled prevalence of apathy was > 50% in LBD and > 40% in prodromal disease stages. Apathy may have utility in earlier, more accurate diagnosis of dementia with Lewy bodies.
- 3 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70425
Open AccessThe prevalence of apathy in Lewy body dementia: A systematic review and meta‐analysis
INTRODUCTION: Apathy is an important syndrome in Lewy body dementia (LBD), although reported prevalences vary. We aimed to estimate the prevalence of apathy in LBD through systematic review and meta‐analysis. METHODS: Five databases were searched for articles reporting the prevalence of apathy in LBD (dementia with Lewy bodies [DLB] and Parkinson's disease dementia [PDD]) and prodromal/mild cognitive impairment (MCI) LBD. Linear mixed model random effect meta‐analysis was performed to determine the prevalence of apathy. RESULTS: Of 7846 articles identified, 49 met inclusion criteria. The average pooled prevalence of apathy was 57% (95% confidence interval [CI] 52%–63%, I 2 = 85.6%) in DLB, 56% (95% CI 43%–70%, I 2 = 97.6%) in PDD, 46% (95% CI 32%–61%, I 2 = 90.6%) in Lewy body‐MCI, and 38% (95% CI 25%–50%, I 2 = 88.1%) in Parkinson's disease‐MCI. DISCUSSION: Apathy affects more than half of individuals with LBD. The high prevalence in prodromal DLB supports the notion that apathy may assist in more timely and accurate diagnosis of DLB. Highlights: Reported apathy prevalence in Lewy body dementia (LBD) varies widely in the existing literature. The pooled prevalence of apathy was > 50% in LBD and > 40% in prodromal disease stages. Apathy may have utility in earlier, more accurate diagnosis of dementia with Lewy bodies.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Investigation of inflammation in Lewy body dementia: a scoping review
Background: Inflammatory mechanisms are increasingly recognized as part of the pathogenesis of neurodegenerative diseases, including Lewy body dementia (LBD). Advances in analytical techniques using in vivo and postmortem samples have been applied to address questions of key mechanisms and relevance to clinical manifestations. Our primary objective was to review methods used to investigate inflammation in LBD (dementia with Lewy bodies and Parkinson’s disease dementia), and how these are applied to conceptualise inflammation. Our secondary objective was to identify alterations in inflammatory signals in LBD compared to people without neurodegenerative disease, and compared to related neurodegenerative disease, in particular AD and PD.Method: A scoping review was performed by identifying relevant human studies that investigated inflammation in LBD. The major electronic databases MEDLINE, Embase, Web of Science, and PSYCHInfo were searched. Two authors performed abstract screening and full text review.Result: Of 1970 results screened, 65 studies were included. Twenty‐nine studies analysed postmortem brain tissue and 35 included living subjects. Largely cross‐sectional data were available, although 2 longitudinal clinical studies of prodromal Lewy body disease were noted. Analysis of biofluid (blood and cerebrospinal fluid) was the most common in vivo method used (n = 31) and 3 studies investigated LBD genetics. Investigations were focused on inflammatory immune cell activity (microglia, astrocytes, lymphocytes), and molecules linked to inflammation (e.g., cytokines). Results of included studies supported innate and adaptive immune system contribution to inflammation associated with Lewy body pathology and clinical features of the disease. Different signals in early and late‐stage disease, with possible late immune senescence including dystrophic microglia and altered adaptive immunity, were distinct from Alzheimer’s disease. The strength of these associations is limited by the varying methodologies, small study sizes and cross‐sectional nature of data.Conclusion: Current investigation of inflammation in LBD utilises substrate collected from early to late‐stage disease. Strengths and limitations of the range of analytical techniques used must be considered when forming conclusions. Longitudinal data that informs associations with clinical and other biomarker outcomes is needed to improve understanding of inflammatory activity over the disease course of LBD. This could identify markers of disease activity and therapeutic targets.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessInvestigation of inflammation in Lewy body dementia: a scoping review
Background: Inflammatory mechanisms are increasingly recognized as part of the pathogenesis of neurodegenerative diseases, including Lewy body dementia (LBD). Advances in analytical techniques using in vivo and postmortem samples have been applied to address questions of key mechanisms and relevance to clinical manifestations. Our primary objective was to review methods used to investigate inflammation in LBD (dementia with Lewy bodies and Parkinson’s disease dementia), and how these are applied to conceptualise inflammation. Our secondary objective was to identify alterations in inflammatory signals in LBD compared to people without neurodegenerative disease, and compared to related neurodegenerative disease, in particular AD and PD.Method: A scoping review was performed by identifying relevant human studies that investigated inflammation in LBD. The major electronic databases MEDLINE, Embase, Web of Science, and PSYCHInfo were searched. Two authors performed abstract screening and full text review.Result: Of 1970 results screened, 65 studies were included. Twenty‐nine studies analysed postmortem brain tissue and 35 included living subjects. Largely cross‐sectional data were available, although 2 longitudinal clinical studies of prodromal Lewy body disease were noted. Analysis of biofluid (blood and cerebrospinal fluid) was the most common in vivo method used (n = 31) and 3 studies investigated LBD genetics. Investigations were focused on inflammatory immune cell activity (microglia, astrocytes, lymphocytes), and molecules linked to inflammation (e.g., cytokines). Results of included studies supported innate and adaptive immune system contribution to inflammation associated with Lewy body pathology and clinical features of the disease. Different signals in early and late‐stage disease, with possible late immune senescence including dystrophic microglia and altered adaptive immunity, were distinct from Alzheimer’s disease. The strength of these associations is limited by the varying methodologies, small study sizes and cross‐sectional nature of data.Conclusion: Current investigation of inflammation in LBD utilises substrate collected from early to late‐stage disease. Strengths and limitations of the range of analytical techniques used must be considered when forming conclusions. Longitudinal data that informs associations with clinical and other biomarker outcomes is needed to improve understanding of inflammatory activity over the disease course of LBD. This could identify markers of disease activity and therapeutic targets.
- Open Access
- 28 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12116
Investigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review
Inflammatory mechanisms are increasingly recognized as important contributors to the pathogenesis of neurodegenerative diseases, including Lewy body dementia (LBD). Our objectives were to, firstly, review inflammation investigation methods in LBD (dementia with Lewy bodies and Parkinson’s disease dementia) and, secondly, identify alterations in inflammatory signals in LBD compared to people without neurodegenerative disease and other neurodegenerative diseases. A systematic scoping review was performed by searching major electronic databases (MEDLINE, Embase, Web of Science, and PSYCHInfo) to identify relevant human studies. Of the 2509 results screened, 80 studies were included. Thirty-six studies analyzed postmortem brain tissue, and 44 investigated living subjects with cerebrospinal fluid, blood, and/or brain imaging assessments. Largely cross-sectional data were available, although two longitudinal clinical studies investigated prodromal Lewy body disease. Investigations were focused on inflammatory immune cell activity (microglia, astrocytes, and lymphocytes) and inflammatory molecules (cytokines, etc.). Results of the included studies identified innate and adaptive immune system contributions to inflammation associated with Lewy body pathology and clinical disease features. Different signals in early and late-stage disease, with possible late immune senescence and dystrophic glial cell populations, were identified. The strength of these associations is limited by the varying methodologies, small study sizes, and cross-sectional nature of the data. Longitudinal studies investigating associations with clinical and other biomarker outcomes are needed to improve understanding of inflammatory activity over the course of LBD. This could identify markers of disease activity and support therapeutic development.
- 28 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12116
Open AccessInvestigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review
Inflammatory mechanisms are increasingly recognized as important contributors to the pathogenesis of neurodegenerative diseases, including Lewy body dementia (LBD). Our objectives were to, firstly, review inflammation investigation methods in LBD (dementia with Lewy bodies and Parkinson’s disease dementia) and, secondly, identify alterations in inflammatory signals in LBD compared to people without neurodegenerative disease and other neurodegenerative diseases. A systematic scoping review was performed by searching major electronic databases (MEDLINE, Embase, Web of Science, and PSYCHInfo) to identify relevant human studies. Of the 2509 results screened, 80 studies were included. Thirty-six studies analyzed postmortem brain tissue, and 44 investigated living subjects with cerebrospinal fluid, blood, and/or brain imaging assessments. Largely cross-sectional data were available, although two longitudinal clinical studies investigated prodromal Lewy body disease. Investigations were focused on inflammatory immune cell activity (microglia, astrocytes, and lymphocytes) and inflammatory molecules (cytokines, etc.). Results of the included studies identified innate and adaptive immune system contributions to inflammation associated with Lewy body pathology and clinical disease features. Different signals in early and late-stage disease, with possible late immune senescence and dystrophic glial cell populations, were identified. The strength of these associations is limited by the varying methodologies, small study sizes, and cross-sectional nature of the data. Longitudinal studies investigating associations with clinical and other biomarker outcomes are needed to improve understanding of inflammatory activity over the course of LBD. This could identify markers of disease activity and support therapeutic development.
- 11 April 2021
- Published by Wiley in International Journal of Mental Health Nursing
- Vol. 30 (5) , 1183-1192
Aggressive patient behaviours and unplanned nursing staff leave – is there an association?
Mental health nurses are exposed to high levels of aggressive and challenging patient behaviours. This can cause stress and burnout which is associated with poor staff, patient, and organization outcomes, including unplanned nursing staff leave (UNSL). This study explores the correlation between a patient behaviour tool (RAGE), variations of which are frequently used in mental health and psychogeriatric nursing, and the staff outcome of UNSL. The study is reported according to the STROBE Statement for reporting of observational studies. RAGE scores and ward characteristics were recorded weekly for 26 weeks on an Australian metropolitan psychogeriatric ward and correlated with UNSL for the same week and the following week (allowing for any ‘lag effect’ behaviours may have on leave). There was a moderate negative correlation between mean RAGE score and UNSL for the same week (r = −0.34) and no correlation the following week (r = 0.08). Similarly, there was low to no correlation between ward characteristics and UNSL. The trends seen in this exploratory study should be further interrogated in adequately powered future studies. UNSL is likely influenced by complex factors including staff experience, coping mechanism, and specific patient behaviours such as physical or verbal aggression and whether the behaviours resulted in injury, which should be included in future studies. The novel strategy of utilizing patient‐centred tools to predict staff outcomes is feasible and warrants further exploration.
- 11 April 2021
- Published by Wiley in International Journal of Mental Health Nursing
- Vol. 30 (5) , 1183-1192
Aggressive patient behaviours and unplanned nursing staff leave – is there an association?
Mental health nurses are exposed to high levels of aggressive and challenging patient behaviours. This can cause stress and burnout which is associated with poor staff, patient, and organization outcomes, including unplanned nursing staff leave (UNSL). This study explores the correlation between a patient behaviour tool (RAGE), variations of which are frequently used in mental health and psychogeriatric nursing, and the staff outcome of UNSL. The study is reported according to the STROBE Statement for reporting of observational studies. RAGE scores and ward characteristics were recorded weekly for 26 weeks on an Australian metropolitan psychogeriatric ward and correlated with UNSL for the same week and the following week (allowing for any ‘lag effect’ behaviours may have on leave). There was a moderate negative correlation between mean RAGE score and UNSL for the same week (r = −0.34) and no correlation the following week (r = 0.08). Similarly, there was low to no correlation between ward characteristics and UNSL. The trends seen in this exploratory study should be further interrogated in adequately powered future studies. UNSL is likely influenced by complex factors including staff experience, coping mechanism, and specific patient behaviours such as physical or verbal aggression and whether the behaviours resulted in injury, which should be included in future studies. The novel strategy of utilizing patient‐centred tools to predict staff outcomes is feasible and warrants further exploration.
- 19 July 2019
- Published by Wiley in Australasian Journal on Ageing
- Vol. 39 (1) , e77-e85
Outcomes of hospital in the home treatment of acute decompensated congestive cardiac failure compared to traditional in‐hospital treatment in older patients
Objectives: To compare the outcomes of readmission, mortality and treatment‐related complications in older people treated by hospital in the home (HITH) for acute decompensated congestive cardiac failure (CCF) with those treated in hospital.Methods: Retrospective cohort study of patients 65 years and older treated by HITH over a 30‐month period compared with age‐ and sex‐matched patients treated in hospital.Results: There was no difference between the “HITH” and “Hospital” cohorts in mortality within 60 days of discharge (P = 0.5), time to death (P = 0.8), 30‐day (P = 0.7) and 60‐day (P = 0.4) readmissions, time to readmission (P = 0.9) and complication rate (P = 0.1). HITH patients had longer length of stay (P = 0.001) but lower cost per day of admission ($669.42 vs $1377.58).Conclusion: In appropriately selected older patients, HITH is a safe, efficacious and cost‐effective alternative to inpatient management of acute decompensated CCF.
- 19 July 2019
- Published by Wiley in Australasian Journal on Ageing
- Vol. 39 (1) , e77-e85
Outcomes of hospital in the home treatment of acute decompensated congestive cardiac failure compared to traditional in‐hospital treatment in older patients
Objectives: To compare the outcomes of readmission, mortality and treatment‐related complications in older people treated by hospital in the home (HITH) for acute decompensated congestive cardiac failure (CCF) with those treated in hospital.Methods: Retrospective cohort study of patients 65 years and older treated by HITH over a 30‐month period compared with age‐ and sex‐matched patients treated in hospital.Results: There was no difference between the “HITH” and “Hospital” cohorts in mortality within 60 days of discharge (P = 0.5), time to death (P = 0.8), 30‐day (P = 0.7) and 60‐day (P = 0.4) readmissions, time to readmission (P = 0.9) and complication rate (P = 0.1). HITH patients had longer length of stay (P = 0.001) but lower cost per day of admission ($669.42 vs $1377.58).Conclusion: In appropriately selected older patients, HITH is a safe, efficacious and cost‐effective alternative to inpatient management of acute decompensated CCF.